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?Abstract 
Genome-wide association studies have generally failed to identify polymorphisms associated with 
antidepressant response. Possible reasons include limited coverage of genetic variants that this 
study tried to address by exome genotyping and dense imputation.  
A meta-analysis of Genome-Based Therapeutic Drugs for Depression (GENDEP) and Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) studies was performed at SNP, gene and 
pathway level. Coverage of genetic variants was increased compared to previous studies by adding 
exome genotypes to previously available genome-wide data and using the Haplotype Reference 
Consortium panel for imputation. Standard quality control was applied. Phenotypes were symptom 
improvement and remission after 12 weeks of antidepressant treatment. Significant findings were 
investigated in NEWMEDS consortium samples and Pharmacogenomic Research Network 
Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) for replication.  
7,062,950 SNPs were analysed in GENDEP (n=738) and STAR*D (n=1409). rs116692768 
(p=1.80e-08, ITGA9 (integrin alpha 9)) and rs76191705 (p=2.59e-08, NRXN3 (neurexin 3)) were 
significantly associated with symptom improvement during citalopram/escitalopram treatment. At 
gene level, no consistent effect was found. At pathway level, the Gene Ontology terms GO:0005694 
(chromosome) and GO:0044427 (chromosomal part) were associated with improvement (corrected 
p=0.007 and 0.045, respectively). The association between rs116692768 and symptom 
improvement was replicated in PGRN-AMPS (p=0.047), while rs76191705 was not. The two SNPs 
did not replicate in NEWMEDS. 
ITGA9 codes for a membrane receptor for neurotrophins and NRXN3 is a transmembrane neuronal 
adhesion receptor involved in synaptic differentiation. Despite their meaningful biological rationale 
for being involved in antidepressant effect, replication was partial. Further studies  may help in 
clarifying their role. 
Keywords: antidepressant, major depression, GWAS, gene, pathway, integrin, neurexin 
?1. Introduction 
Major depressive disorder (MDD) became one of the five leading diseases contributing to 
disability-adjusted life years (DALYs) in 2010 in the US (1). MDD is associated with a huge 
increase in suicide risk (2), poor quality of life (comparable to that observed in severe physical 
disorders such as arthritis and heart disease (3)) and health expenditure (direct costs alone amount 
to 42 billion dollars per year in Europe (4)).  
Despite the availability of antidepressant drugs belonging to different classes, high inter-individual 
variability is observed in response. The lack of reliable and reproducible markers of treatment 
outcome contributes to unsatisfactory response and remission rates as well as to side effect burden, 
poor treatment adherence and early treatment discontinuation (5). Following the observation that 
antidepressant response clusters in families, genetic variants were considered promising biomarkers 
to tailor antidepressant treatments and improve the prognosis of MDD (6, 7). Genome-wide 
association studies (GWAS) were a promising tool to identify the polymorphisms involved in 
antidepressant response after the overall contradictory and non-replicated findings of candidate 
gene studies (8). But GWAS results fell below expectations, with no genome-wide significant 
signal (p<5e-08) that was replicated in different samples (9-15). Possible reasons for these 
disappointing results include: 1) limited coverage of genetic variants (e.g. ~ 500 K common 
polymorphisms were originally analyzed in STAR*D, GENDEP and MARS studies and ~ 1.2 
millions in the meta-analysis of these studies thanks to imputation, while ~ 40 millions 
polymorphisms are known to date thanks to sequencing studies (9-11) (12, 16); 2) limited sample 
size; 3) sample heterogeneity (e.g. different subtypes of depression and severity, different 
antidepressants); 4) analysis of common variants (minor allele frequency (MAF) > 0.01) alone. 
Further, previous GWAS meta-analyses focused on single marker analysis and pathway analysis 
was performed in single samples and not as meta-analysis among different samples (12, 17). 
Considering these limitations, the current study aimed to:
1) Increase the coverage of genetic variants by analysing exonic polymorphisms and dense 
imputation; 
2) Test for association with antidepressant response at the level of SNPs, genes and pathways 
including both common and rare variants;  
3) Reduce heterogeneity in treatment by analysing patients treated with the same 
antidepressant, as performed previously  (e.g. (10, 17)). 
In addition to the discovery samples of GENDEP and STAR*D, two replication samples were 
available (NEWMEDS and PGRN-AMPS). 
?2. Materials and methods 
2.1 Samples 
2.1.1 GENDEP 
The Genome-Based Therapeutic Drugs for Depression (GENDEP) project was a 12-week partially 
randomized open-label pharmacogenetic study with two active treatment arms. 867 patients with 
unipolar depression (ICD-10 or DSM-IV criteria) aged 1972 years were recruited at nine European 
centres. Eligible participants were allocated to flexible-dosage treatment with either escitalopram 
(1030 mg daily, 499 subjects) or nortriptyline (50150 mg daily, 368 subjects). Severity of 
depression was assessed weekly by the Montgomery-Asberg Depression Rating Scale (MADRS) 
(18), Hamilton Rating Scale for Depression (HRSD17) (19) and Beck Depression Inventory (BDI) 
(20). Detailed information about the GENDEP study has been previously reported (10). 736 
subjects had no missing phenotypes and covariates after quality control (see quality control details 
in paragraph 2.3.Genotyping and imputation) and they were included in this study. 
2.1.2 STAR*D 
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was a NIMH-
funded study aimed to determine the effectiveness of different treatments for patients with MDD 
who have not responded to the first antidepressant treatment. Non-psychotic MDD (DSM-IV 
criteria) patients with age between 18 and 75 years were enrolled from primary care or psychiatric 
outpatient clinics. Severity of depression was assessed using the 16-item Quick Inventory of 
Depressive Symptomatology-Clinician Rated (QIDS-C16) (21) at baseline, weeks 2, 4, 6, 9, and 12, 
while HRSD17 was administered at each level entry and exit. All patients received citalopram in 
level 1 and the present study is based on level 1 data. 1953 patients were included in the genetic 
study. Detailed description of the study design and population are reported elsewhere (22). 1409 
subjects had no missing phenotypes and covariates after quality control (see quality control details 
in paragraph 2.3.Genotyping and imputation) and they were included in this study. 
2.1.3 Replication samples 
NEWMEDS consortium (http://www.newmeds-europe.com) (23) samples other than GENDEP (17) 
and PGRN-AMPS (Pharmacogenomic Research Network Antidepressant Medication 
Pharmacogenomic Study) sample (14) were used for replication of significant findings obtained in 
the GENDEP-STAR*D meta-analysis.  
As part of the NEWMEDS consortium (for further details see (17)), three studies conducted by
academic institutions (GENDEP, see paragraph 2.1.1; GENPOD, a randomized controlled trial of 
two active antidepressants, n=601 (24); and GODS, a treatment cohort of severe depression, n=131 
(25)) and two studies by pharmaceutical industry members of the European Federation of 
?Pharmaceutical Industries and Associations (active comparator arms from randomized controlled 
trials by Pfizer, n=355, and GlaxoSmithKline, n=191) were combined. All included patients were 
diagnosed with MDD and treated for 6 to 12 weeks with either an antidepressant that acts primarily 
through blocking the reuptake of serotonin (SSRIs: escitalopram, citalopram, paroxetine, sertraline, 
fluoxetine) or an antidepressant that acts primarily through blocking the reuptake of norepinephrine 
(NRIs: nortriptyline, reboxetine), see (17) for details. 980 subjects had no missing phenotypes and 
covariates after quality control (see quality control details in paragraph 2.3.Genotyping and 
imputation) and they were included in this study. 
PGRN-AMPS included 529 participants with nonpsychotic MDD who were recruited at the Mayo 
Clinic in Rochester, Minnesota primarily through the inpatient and outpatient practices of the 
Department of Psychiatry and Psychology. Participants were offered an eight-week course of 
treatment with either citalopram or escitalopram and depressive symptoms were rated using QIDS-
C16 as in the STAR*D study in addition to the HRSD17. For further details see (14). 492 subjects 
had no missing phenotypes and covariates after quality control (see quality control details in 
paragraph 2.3.Genotyping and imputation) and they were included in this study. 
2.2 Outcomes  
The primary outcome of this study was depressive symptom improvement after 12 weeks of 
antidepressant treatment. Continuous measures, such as percentage improvement, capture more 
information and have higher power than cutoff-based dichotomous measures, such as remission, 
however remission was associated with MDD prognosis (26) (27). The percentage change in scores 
between baseline and 12 weeks was used to measure symptom improvement, using MADRS in the 
GENDEP study, and QIDS-C16 in STAR*D, as in previous studies in these samples (10, 28).  
As a secondary outcome, we investigated symptom remission after 12 weeks of antidepressant 
treatment. According to standard criteria, remission was defined as HRSD17 ≤ 7 (29) and QIDS-
C16 ≤ 5 (28) in GENDEP and STAR*D, respectively. HRSD17 was used to define remission in 
the GENDEP given the stronger consensus about the threshold to identify remission on this scale in 
contrast to MADRS, where different definitions of remission have been reported (≤ 12 (30), ≤ 10 
(31), ≤ 8 (32)).   
Each outcome measure (percentage change, remission) was analyzed separately in GENDEP and 
STAR*D, and then a meta-analysis performed.  Two analyses were performed, initially using all 
samples, and then including only escitalopram-treated patients from GENDEP, since escitalopram 
is the active isomer of citalopram (33), the antidepressant used in STAR*D level 1.  
Missing data were handled as in previous studies on the investigated samples (9, 10). When at least 
one post-baseline assessment was available, the percentage improvement at 12 weeks was estimated 
?as the best unbiased estimate of mixed effect linear models. Participants without any post-baseline 
measurement were excluded from the analyses. Since specific antidepressant response is associated 
with depression severity (34), a minimum depression severity score of 14 on the HRSD17 was an 
inclusion criterion in the STAR*D study (all the subjects that we included satisfied this criteria) but 
not in GENDEP thus a sensitivity analysis excluding GENDEP subjects with HRSD17<14 was 
performed for the validation of significant findings.  
2.3.Genotyping and imputation 
Genome-wide data available in STAR*D were obtained using Affymetrix Human Mapping 500K 
Array Set in 969 subjects and Affymetrix Genome-Wide Human SNP Array 5.0 (Affymetrix, South 
San Francisco, California) in the remaining 979 samples, while in GENDEP Illumina Human610-
quad bead chip (Illumina, Inc., San Diego) was used  (9, 10). In STAR*D the two groups genotyped 
by different arrays were balanced by ethnic grouping, gender and proportions of responders and 
non-responders. Twelve samples were genotyped on both the 500K and 5.0 Arrays, and > 99% 
concordance was found across these platforms (9). Further genotyping in both samples was 
performed by the Illumina Infinium Exome-24 v1.0 BeadChip that includes ~ 250K variants. Pre-
imputation quality control was performed according to the following criteria: 1) variants with 
missing rate ≥ 5%; 2) monomorphic variants; 3) subjects with genotyping rate < 97%; 4) subjects 
with gender discrepancies; 5) subjects with abnormal heterozygosity; 6) related subjects (identity by 
descent (IBD) >0.1875 (35)); 7) population outliers according to Eigensoft analysis of linkage-
disequilibrium-pruned genetic data (36, 37); 8) GWAS discordant subjects (referred to exome data 
only) and 9) non-white subjects (referred to STAR*D only since all subjects included in the 
GENDEP are of Caucasian ethnicity). HardyWeinberg equilibrium was not used as an exclusion 
criterion for markers (as previously done in the same datasets (17)), since departures from Hardy
Weinberg equilibrium are expected in a case-only study (38). 
Data were imputed using Minimac3 as provided by the Michigan imputation Server 
(https://imputationserver.sph.umich.edu/start.html). Post-imputation quality control was performed 
pruning variants according to the following criteria: 1) poor imputation quality (R
2
 < 0.30 (39, 40); 
2) minor allele frequency (MAF) < 0.01 (see further details in paragraph 2.4 Statistical analysis).  
For a flow chart describing pre- and post-imputation quality control on each dataset see 
Supplementary Figure 1. Since exome array data were available only in 1015 subjects from the 
STAR*D sample (after quality control), the imputation of these data was performed separately from 
the imputation of genome-wide array data (1470 subjects). 
2.4 Statistical analysis 
?We performed a fixed-effects meta-analysis to test the association between single polymorphisms 
and phenotypes using PLINK (41). Heterogeneity measures (Cochranes Q statistic and the I
2
heterogeneity index) were calculated. We tested linear or logistic regression models including the 
ancestry-informative principal components, recruitment centre, age, and baseline severity as 
covariates in line with previous publications on these samples (10, 12, 42). The same covariates 
were used for gene and pathway analysis. 
We tested the association between genes and phenotypes as well as pathways and phenotypes using 
MAGMA (43). MAGMA performs both a self-contained and a competitive gene-set analysis, the 
latter is more conservative and it was applied in this study since it reflects the difference in 
association between genes in the pathway and genes outside the pathway. Only for the replication 
analyses self-contained analysis results were also reported since the replication nature of these tests. 
Both rare (MAF<0.01) and common variants were included in gene and pathway analysis, but only 
genotyped rare variants were retained while imputed rare variants were excluded. Indeed imputation 
quality of rare variants using the HRC panel was found to be better than using 1000 Genomes data 
(R
2
=0.64 vs R
2
=0.36 at MAF=0.1% when using a 1M SNP chip) but we preferred to be 
conservative (44). Thus we chose a relatively conservative approach, including only subjects 
genotyped on both genome-wide and exome array in the gene and pathway analysis. In the gene- 
and pathway-level meta-analysis different weights were assigned to polymorphisms according to 
their MAF, thus higher weight was assigned to rare variants as implemented in MAGMA (43). 
For pathway analysis in each dataset and their meta-analysis the reported results refer to a 
competitive gene-set analysis, which uses a conditional model to correct for confounding due to 
gene size, gene density and (if applicable) differences in sample size per gene (43). The analysed 
pathways were downloaded from http://software.broadinstitute.org/gsea/downloads.jsp (Biocarta, 
KEGG, Gene Ontology, Reactome, microRNA targets and transcription factor targets).  
An attempt to replicate significant results was performed in NEWMEDS (omitting GENDEP) and 
PGRN-AMPS. In NEWMEDS phenotypes and covariates were as described in a previous study 
(17). Briefly, percent symptom improvement at end-point was adjusted for covariates (age, gender, 
baseline severity, ancestry-informative principal components and centre in case of multi-centric 
studies) and z-score transformed. Samples were genotyped on Illumina Human610-Quad 
BeadChips or Illumina Human660W-Quad BeadChips.  
For PGRN-AMPS details about phenotypes and covariates were described elsewhere (14).  Percent 
symptom improvement at end-point was used as phenotype and covariates were the first four 
population principal components and age as in the original GWAS (14). Samples were genotyped 
on Illumina Human610-Quad BeadChips (Illumina, San Diego, CA). 
?In both replication samples we performed genotype imputation using the same method applied in 
GENDEP and STAR*D; pre- and post-imputation quality control were performed according to the 
same criteria. For replication of individual SNP results, the index SNP and those in linkage 
disequilibrium (R
2≥0.30) were considered. 
 2.5 Multiple-testing correction and power analysis 
For individual SNP analysis, a genome-wide significance threshold was set at p=5e-08. A 
suggestive significance threshold was set at a p value of 5e-06, which is two orders of magnitude 
below the genome-wide significance level and approximately corresponds to a level at which one 
association per genome-wide analysis is expected by chance (45). A nominal p value of 0.05 was 
set for replication of significant findings in NEWMEDS and PGRN-AMPS since no genome-wide 
analysis was performed in these samples. 
For MAGMA gene level analysis, the False Discovery Rate (FDR) correction was applied. For 
MAGMA pathway analysis, 50,000 permutations were performed to correct for multiple testing.  
For a continuous outcome in the whole sample (n=2145) and setting alpha=5e-08, we had 80% 
power to identify a SNP with an effect size (heritability) of 0.018, while in citalopram-escitalopram 
treated sample (n=1739) we had 80% power to identify an effect size of 0.022 (46).  
For a dichotomous phenotype in the whole sample and setting alpha=5e-08, we had 80% power to 
identify a risk allele with MAF=0.06 and RR=1.50, while in citalopram-escitalopram treated sample 
we had 80% power to identify a risk allele with MAF=0.07 and RR=1.50 (47).  
3. Results 
The clinical-demographic characteristics of the samples are reported in Supplementary Table 1. 
2145 subjects (1409 and 736 from STAR*D and GENDEP, respectively) were included in the SNP-
level meta-analysis, 1828 of them were treated with citalopram or escitalopram. 1739 (1003 and 
736 from STAR*D and GENDEP, respectively) subjects were included in the gene and pathway 
meta-analysis, 1422 of them were treated with citalopram or escitalopram.  
3.1 SNP analysis results 
The GENDEP and STAR*D meta-analysis included 7,062,950 SNPs and showed no evidence of 
genomic inflation (lambda values were ≤ 1.01, QQ-plots are shown in Supplementary Figure 2).  
In the whole sample, no SNP reached the genome-wide significance threshold for association with 
symptom improvement or remission. Eighty SNPs, from 17 genomic regions, reached suggestive 
level of association (p<5e-06) (Supplementary Table 2). 
In STAR*D and escGENDEP (GENDEP escitalopram) meta-analysis, rs116692768 (MAF=0.033, 
beta STAR*D=0.14, beta escGENDEP=-0.20, p=1.87e-08) and rs76191705 (MAF=0.012, beta 
??
STAR*D=-0.26, beta escGENDEP=-0.23, p=2.39e-08) were significantly associated with symptom 
improvement (Figure 1; Table 1). These SNPs are located within introns of the ITGA9 (integrin 
alpha 9) and NRXN3 (neurexin 3) genes. Another NRXN3 SNP (rs79302561) was close to the 
significance threshold (p=6.76e-08). There was no heterogeneity as measured by I
2
 for these three 
SNPs, thus fixed-effects and random-effects p values corresponded. Each SNP was imputed, with 
R
2
 values of over 0.6 for each SNP in each cohort (Table 1). These SNPs retained significance after 
the exclusion of GENDEP patients with baseline HRSD17<14 (p=2.69e-08 and 3.43e-08, 
respectively). Regional association plots for ITGA9 and NRXN3 genes are reported in Figure 2. An 
overview of SNPs with suggestive level of association (p<5e-06) with symptom improvement in 
STAR*D and escGENDEP is reported in Supplementary Table 3. 
In the analysis of remission, no SNPs reached significance in the full meta-analysis or the meta-
analysis with escGENDEP, SNPs with suggestive level of association (p<5e-06) are reported in 
Supplementary Tables 4-5.   
3.2 Gene analysis results 
The gene-level analysis included 17,996 genes with 3,185,134 SNPs, a schematic representation of 
this analysis was reported in Supplementary Figure 3A.  
In the whole sample meta-analysis, the olfactory receptor family 4 subfamily K member 2 (OR4K2) 
gene was associated with symptom improvement after multiple-testing correction (nominal 
p=2.13e-06, corrected p=0.038 (FDR)). OR4K2 included 4 rare genotyped SNPs in both datasets 
but the overall effect of OR4K2 rare alleles on improvement was in the opposite direction between 
the samples. GENDEP subjects carrying rare alleles (rs199718838 A, rs116972349 A, rs151057533 
C and rs147651981 T, n=8 subjects) showed lower mean symptom improvement (18.58±53.43%) 
compared to common alleles carriers (59.78±24.49%), while in STAR*D the opposite was found 
(fourteen subjects carrying rare alleles (rs199718838 A, rs116972349 A, rs142549715 A and 
rs150417989 G) had a mean improvement of 70.30±22.23% compared to a mean improvement of 
50.33±32.98% in common allele carriers).  No gene survived multiple-testing correction in the 
analysis of remission (Supplementary Table 6). 
In the meta-analysis of STAR*D and escGENDEP, no gene was associated with symptom 
improvement or remission (Supplementary Table 7). Several genes with nominal p≤0.0005 
overlapped with those found in the whole sample, such as POU1F1, PAG1, PKM, RPUSD3 and
PARP6. 
3.3 Pathway analysis results 
17,996 genes including 3,185,134 SNPs were included in this analysis, a schematic representation 
of this analysis was reported in Supplementary Figure 3B. 
??
In the whole sample, the Gene Ontology term corresponding to the chromosome pathway 
(GO:0005694) and the chromosomal part (GO:0044427) pathway were associated with symptom 
improvement (corrected p=0.007 and 0.045, respectively). No pathway was associated with 
remission. 
In STAR*D and escGENDEP, the steroid hormone receptor signaling pathway (GO:0030518) was 
very close to the significance threshold for association with remission (corrected p=0.055).  
An overview of results is reported in Table 2 (including all pathways with p<0.10) and the 
functional role of the variants in each of these pathways is shown in Supplementary Figure 4. 
Interestingly, the chromosome pathway (GO:0005694) was the richest in rare missense variants 
(6.6% versus 2.5-3% in the other pathways).  
3.4 Replication samples 
In both replication samples, only the genome-wide significant findings of STAR*DescGENDEP 
meta-analysis and independent SNPs showing R
2≥0.30 with them were analysed. Secondly, 
pathways reported in Table 2 were also investigated. In NEWMEDS replication analyses were 
performed in the whole sample or only in subjects treated with some antidepressants according to 
results in the discovery samples. 980 and 492 subjects were included after quality control in 
NEWMEDS and PGRN-AMPS, respectively. 
In NEWMEDS the two SNPs associated with symptom improvement in the STAR*D  
escGENDEP meta-analysis were not replicated and weak nominal associations were found for two 
SNPs (s7152916 and rs7152941) in LD with NRXN3 rs76191705 in the subsample treated with 
SSRIs (n=751), while trends of association were found in the subsample treated with 
citalopram/escitalopram (n=370) (Supplementary Table 8A). In this sample only three independent 
SNPs in LD with the index SNPs were available. 
Over 90% of SNPs included in the pathways showing significant associations (or trends, see Table 
2) in the GENDEP-STAR*D meta-analysis were available also in NEWMEDS and only these 
pathways were analysed in NEWMEDS. In the subsample treated with citalopram or escitalopram 
(n=370), the intracellular receptor mediated signaling pathway and the steroid hormone receptor 
signaling pathway were associated with improvement (permutated comparative p=0.0028 and 
p=0.017, respectively, self-p=0.0089 and 0.014 (self-p values are also reported because only six 
pathways were analysed here and for a replication purpose, see paragraph 2.4 Statistical analysis for 
details about comparative and self-p values)), other pathways reported in Table 2 did not show 
association with phenotypes.   
In PGRN-AMPS only ITGA9 rs116692768 and NRXN3 rs76191705 were investigated because no 
SNP showed LD≥0.30 with them. rs116692768 was associated with symptom improvement in the 
??
same direction to STAR*D  escGENDEP meta-analysis (p=0.047, Supplementary Table 8B; no 
multiple testing correction was applied here since only two SNPs were investigated for replication 
purpose), while rs76191705 showed no association with this phenotype (p=0.34). 
In PGRN-AMPS only the intracellular receptor mediated signaling pathway and the steroid 
hormone receptor signaling pathway were analysed because all patients were treated with 
citalopram or escitalopram in this sample. Over 90% of SNPs included in these pathways in 
STAR*D  escGENDEP meta-analysis was available in PGRN-AMPS, but no association with 
symptom improvement was found (nominal self-p values were 0.10 and 0.11, respectively). 
4. Discussion 
4.1 Main findings 
The present study has exploited existing pharmacogenetic samples (GENDEP and STAR*D), 
through: 1) the increase of genetic variant coverage (exome genotyping, high-density imputation) 
and 2) SNP-, gene- and pathway-level meta-analysis.  
In the SNP-level meta-analysis, rs116692768 and rs76191705 were associated with symptom 
improvement during citalopram/escitalopram treatment (Table 1), rs116692768 was nominally 
replicated in PGRN-AMPS but none of the two SNPs was replicated in the remaining NEWMEDS 
samples. The effect sizes of these SNPs may appear relatively larger compared to those reported for 
other complex traits, consistently with the findings of other GWAS (the median effect size of 
pharmacogenomics variants was reported to be twice as large as that observed for associations with 
complex disease risk (48)). These SNPs are located within ITGA9 (integrin subunit alpha 9) NRXN3
(neurexin 3), respectively. Both these SNPs are intronic, but the latter is a NMD (non-sense 
mediated decay) transcript variant (i.e. it is a target of NMD). NMD is a post-transcriptional 
surveillance process that recognizes and degrades mRNAs containing premature termination codons 
but it also targets 310% of normal transcripts in humans, thereby serving as a widespread gene 
regulatory mechanism (49-51). rs79302561 T allele was reported to act as an enhancer of gene 
expression in several cell types (Ensembl GRCh37 release 84). ITGA9 rs143661452 lies within both 
ITGA9 and ITGA9-AS1 (antisense RNA). Antisense RNAs are involved in multiple regulatory 
processes in eukaryotes, such as transcriptional interference and RNA masking (52). No regulatory 
role of rs143661452 is known so far. 
The proteins coded by ITGA9 and NRXN3 show interesting functions in relation to antidepressant 
action. Integrins are heterodimeric (one alpha and one beta subunit) transmembrane proteins that 
connect the extracellular environment to intracellular signaling. In the CNS they are involved in the 
control of synaptic plasticity, long-term potentiation (LTP), cell adhesion and migration (53, 54). 
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Polymorphisms in another beta isoform (ITGB3) and expression level of this gene have been 
associated with antidepressant response in humans (42, 55). Neurexins are type I transmembrane 
neuronal adhesion receptors and their interaction with neuroligins is sufficient to trigger 
postsynaptic and presynaptic differentiation (56).  
Non-genome-wide significant SNPs showing suggestive p-values (<5e-06) were mainly intergenic 
but several of them lie in genes previously reported to be involved in mood disorders or 
antidepressant response (particularly SORCS2, GRIN2D, CTNND2, CSGALNACT1, DISC1, 
TSNAX-DISC1) (57-66).  
The gene-level meta-analysis did not show any consistent finding. Indeed the olfactory receptor 
family 4 subfamily K member 2 (OR4K2) gene reached the significance threshold (Supplementary 
Table 6) but the effect of rare alleles on symptom improvement had opposite direction between 
GENDEP and STAR*D. Olfactory receptor genes have been shown to be over-represented among 
homozygous loss of function (HLOF) genes and segregating polymorphisms of functional and non-
functional copies of olfactory genes are common (67). The olfactory receptor family is the most 
polymorphic family of genes in humans after the major histocompatibility complex and the 
phenotypic consequences of such genetic variability are not completely clear but likely not dramatic 
given their large diffusion (68).  
Our pathway meta-analysis in GENDEP-STAR*D showed that the chromosome pathway 
(GO:0005694) and the chromosomal part (GO:0044427) pathway were associated with symptom 
improvement. These pathways were not associated with improvement in NEWMEDS, but 
GO:0044427 and particularly GO:0005694 were much richer in rare missense variants compared to 
the other significant pathways (Supplementary Figure 3) and this may have limited the replicability 
of the finding since no exome genotyping was performed in NEWMEDS. Interestingly, the 
chromosomal part pathway has been previously associated with antidepressant response by a 
genome-wide gene expression study (69). Among the top genes of the chromosome and 
chromosomal part pathways (Table 2), some are involved in the differentiation of neural stem cells 
into neurons (UPF1 (Regulator Of Nonsense Transcripts Homolog), HMGB1 (High Mobility 
Group Box 1) and neural development (FOXC1 (Forkhead Box C1) (70-72)). Thus these genes may 
play a role in the neurogenesis process that is known to mediate the effect of antidepressants. 
Another member of these pathways is PAM (Peptidylglycine Alpha-Amidating Monooxygenase) 
that acts as a regulator of amygdala excitability and synaptic plasticity (73) and consistently it plays 
a role in emotional responses regulation (74).  
The meta-analysis of escGENDEP and STAR*D showed that the steroid hormone receptor 
signaling pathway and the intracellular receptor mediated signaling pathway (that largely overlap 
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between each other) were close to the significance threshold after permutations. Impaired 
glucocorticoid receptor (GR) function has been suggested to be causal for HPA axis hyperactivity 
in MDD that results in impaired neurogenesis and reduction of hippocampal volume. 
Antidepressants modulate the expression of GR, its translocation to the nucleus and also the 
transcription of its target genes (75). The steroid hormone receptor signaling pathway and the 
intracellular receptor mediated signaling pathway were associated with improvement in 
NEWMEDS citalopram-escitalopram treated subsample but not in PGRN-AMPS. YWHAH was one 
of the top genes of this pathway found in both discovery sample and NEWMEDS. YWHAH codes 
for the η subtype of the 14-3-3 protein family, it is expressed mainly in the brain, and it is a positive 
regulator in the glucocorticoid signal pathway by blocking the degradation of the GR. Variants in 
this genes have been associated with bipolar disorder and schizophrenia (76).  
4.2 Limitations 
The limitations of the present study should be considered. First, the samples included in this study 
(particularly NEWMEDS samples used for replication) were heterogeneous from several points of 
view, for example baseline severity, scales used to assess depressive symptoms, time points of 
evaluation, antidepressant treatment and dose, setting of recruitment. Heterogeneity across samples 
and small size of replication samples have limited the power to replicate our findings. In GENDEP 
and part of STAR*D exome genotypes were available (Illumina Infinium Exome-24 v1.0 
BeadChip) but these were not genotyped in the replication samples, making it difficult to replicate 
the gene and pathway analysis findings. Antidepressant response is known to be a heterogenous 
phenotype that is affected by a number of genetic and non-genetic variables. In this study we 
considered age, baseline severity, recruitment centre and ancestry-informative principal components 
as covariates and we investigated genes and pathways as analysis units in addition to individual 
SNPs, but there are presumably a number of factors that we did not take into account, such as the 
effect of the environment. MDD was demonstrated to be genetically heterogeneous, since 
independent samples showed relatively low genetic correlation compared to schizophrenia and 
bipolar disorder (77) . The significant SNPs that we identified explained a limited percent of 
variance in symptom improvement (rs116692768 explained 3.5% and rs76191705 2.7% in 
escGENDEP, while both variants explained ~ 1.4% of phenotypic variance in STAR*D), that is not 
expected to be clinically significant. Indeed it has been suggested that a variant explaining 6.3% of 
variance may be considered as clinically meaningful (78). Placebo response is another issue not 
taken into account by antidepressant pharmacogenomics trials, despite placebo response was 
reported to significantly contribute to the antidepressant effect and to have a relevant genetic 
component (79). Finally, the replication of findings was weak or absent and no validation of the 
??
results was obtained through the use of complementary investigation strategies such as gene 
expression studies.   
4.3 Conclusions 
The increase in genetic variant coverage seems useful to identify new variants that may influence 
antidepressant efficacy, but the difficulty in signal replication across different samples is still a 
problem. Adequate sample size represents a primary issue to allow replication, but also the use of 
standardized criteria for patient inclusion, treatment and evaluation. The identification of more 
homogenous groups of patients appears a critical issue in MDD and antidepressant 
pharmacogenomics. Results of pathway analysis and more in general gene set analysis may be 
easier to replicate across different samples than individual SNPs because sources of heterogeneity 
or bias (e.g. genotyping or imputation errors) are expected to have a lower influence and effect sizes 
are expected to be higher than for individual SNPs. LD score regression and polygenic risk scoring 
are recent complementary approaches that are expected to provide a relevant contribution to the 
study of the polygenic complexity of antidepressant response and the sharing of genetic variants 
with correlated traits, such as MDD, response to other psychotropic drugs or placebo response.  
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Figure 1: Manhattan plot for meta-analysis of association with symptom improvement in STAR*D 
and GENDEP escitalopram-treated subsample.  
Figure 2: regional association plots for ITGA9 (A) and NRXN3 (B) and symptom improvement in 
STAR*D and GENDEP escitalopram-treated subsample. Plots were obtained using LocusZoom 
(locuszoom.org/). Imputed SNP are plotted as squares and genotyped (in at least one sample) SNPs 
as circles.  
A 
B 
Table 1: SNPs showing genome-wide association with symptom improvement in GENDEP escitalopram-treated sample and STAR*D meta-
analysis. Chr=chromosome. Pos=position (GRCh37). Q=Cochrane’s Q statistic. I=I
2
 heterogeneity index. Rsq=measure of imputation quality. 
MAF=minor allele frequency. Random and fixed p values corresponded for these SNPs. 
SNP Chr Base pair Gene P Q I Rsq STARD/escGENDEP Beta STARD/escGENDEP MAF STARD /escGENDEP 
rs116692768 3 37540482 ITGA9(intron) 1.87e-08 0.36 0 0.75 / 0.78 -0.14 /  -0.20 0.035 / 0.023 
rs76191705 14 79718462 NRXN3(intron) 2.39e-08 0.76 0 0.61 / 0.96 -0.26 / -0.23 0.010 / 0.016 
Table 2: results of pathway meta-analysis in the whole sample and STAR*D  GENDEP escitalopram 
subgroup (CIT-ESCI). Results with corrected (permutated) p < 0.10 are reported. For each pathway Top 
genes are those showing nominal p ≤ 0.10 for association with the phenotype.   
Pathway Sample - 
Phenotype 
N genes Top genes P 
Chromosome pathway 
(GO:0005694) 
Whole sample - 
improvement 
116 NPM2, PAM, BUB1, UPF1, POLG2, 
NDC80, RFC4, HMGB1, FOXC1, 
TIPIN, SMC2, TOP1, H2AFY, OIP5  
0.0069 
Chromosomal part 
(GO:0044427) 
92 NPM2, PAM, BUB1, UPF1, NDC80, 
RFC4, FOXC1, SMC2, TIPIN, OIP5, 
H2AFY 
0.045 
Targets of JUN 247 CCNA2, GPBP1, VGF, GNB4, 
RAI1, RUNDC3A, AHI1, UBE2H, 
ALS2, ABHD16A, SIK1, SLC18A2, 
PDP1, PCSK1, IRF2BPL, ELAVL1, 
ELOVL5, ANAPC10, TIPRL, 
B3GALT2, HOXC10, RPS29, 
ZFAND2B, SYNCRIP, MAP3K13, 
LGR5, RAB25, TSC22D2, 
PACRGL, LENG9, GLI1, TGIF2, 
GPR3, RCE1, ATG5, TRPC1, HHIP, 
SYT11, RBM18 
0.092 
Targets of CREB1 250 CCNA2, GPBP1, VGF, GNB4, 
RAI1, RUNDC3A, AHI1, UBE2H, 
ALS2, ABHD16A, SIK1, SLC18A2, 
PDP1, PCSK1, IRF2BPL, ELAVL1, 
ELOVL5, ANAPC10, TIPRL, 
HOXC10, RPS29, ZFAND2B, 
MAP3K13, RBMS2, LGR5, RAB25, 
TSC22D2, ZNF687, TUBB2B, 
PACRGL, GLI1, TGIF2, GPR3, 
RCE1, ATG5, HHIP, SYT11, 
RBM18
0.094 
Steroid hormone receptor 
signaling pathway 
(GO:0030518) 
CIT-ESCI  
improvement 
18 UBR5 0.070 
Intracellular receptor 
mediated signaling 
pathway (GO:0030522) 
19 UBR5 0.087 
Steroid hormone receptor 
signaling pathway 
(GO:0030518) 
CIT-ESCI  
remission 
18 YWHAH, MED13, DAXX 0.055 
Intracellular receptor 
mediated signaling 
pathway (GO:0030522) 
19 YWHAH, MED13, DAXX 0.079 
